Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Meng Tao, Jing Han, Juanyi Shi, Hao Liao, Kai Wen, Weidong Wang, Sintim Mui, Huoming Li, Yongcong Yan & Zhiyu Xiao. (2023) Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 10, pages 1069-1083.
Read now
Read now
Tao Sun, Yanqiao Ren, Bo Sun, Lei Chen, Licheng Zhu, Lijie Zhang & Chuansheng Zheng. (2023) The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC. Journal of Hepatocellular Carcinoma 10, pages 447-457.
Read now
Read now
Articles from other publishers (15)
Xudan Wang, Weiwei Cao, Yan Qiu, Hongchen Ji, Juzheng Yuan, Weikang Wu, Fuyuan Liu, Liangyong Feng, Rui Ding, Xiao Li & Kaishan Tao. (2023) Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery. Frontiers in Oncology 13.
Crossref
Crossref
Tzu-Rong Peng, Li-Jou Yang & Ta-Wei Wu. (2023) Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis. Tzu Chi Medical Journal.
Crossref
Crossref
Xiaomi Li, Xiaoyan Ding, Mei Liu, Jingyan Wang, Wei Sun, Ying Teng, Yawen Xu, Hongxiao Wu, Wendong Li, Lin Zhou & Jinglong Chen. (2023)
A multicenter prospective study of
TACE
combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
. Cancer Medicine 12:16, pages 16805-16814.
Crossref
Crossref
Ting Li, Jiang Guo, Yushen Liu, Zhaoqing Du, Zhaoyang Guo, Yangwei Fan, Long Cheng, Yue Zhang, Xu Gao, Yunyu Zhao, Xinyuan He, Wenhua Wu, Ning Gao, Yinying Wu, Jie Li, Yu Zhang, Wen Kang, Zhifang Cai, Wenjun Wang, Xiaopeng Li, Ying Zan, Mindie H. Nguyen & Fanpu Ji. (2023) Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC. Cancer Immunology, Immunotherapy 72:7, pages 2137-2149.
Crossref
Crossref
Xu Yang, Bowen Chen, Yanyu Wang, Yunchao Wang, Junyu Long, Nan Zhang, Jingnan Xue, Ziyu Xun, Linzhi Zhang, Jiamin Cheng, Jin Lei, Huishan Sun, Yiran Li, Jianzhen Lin, Fucun Xie, Dongxu Wang, Jie Pan, Ke Hu, Mei Guan, Li Huo, Jie Shi, Lingxiang Yu, Lin Zhou, Jinxue Zhou, Zhenhui Lu, Xiaobo Yang, Yilei Mao, Xinting Sang, Yinying Lu & Haitao Zhao. (2023) Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients. Hepatology International 17:3, pages 709-719.
Crossref
Crossref
Jinbin Chen, Peiyao Xiong, Man Nie, Yangxun Pan, Juncheng Wang, Dandan Hu, Zhongguo Zhou, Yaojun Zhang, Minshan Chen & Li Xu. (2022) The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study. Journal of Cancer Research and Clinical Oncology 149:6, pages 2491-2500.
Crossref
Crossref
Yuwei Liu, Jiahui Pan, Fangbo Gao, Wentao Xu, Hongyu Li & Xingshun Qi. (2022) Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Advances in Therapy 40:2, pages 521-549.
Crossref
Crossref
Zhihong Chen, Zhenrong Chen, Wu Fan, Yiping Zou, Yuanpeng Zhang, Ning Shi & Haosheng Jin. (2023) Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report. World Journal of Surgical Oncology 21:1.
Crossref
Crossref
Huaiyuan Wang, Ge Zhang, Xiaobo Yang, Zhenhui Lu & Haitao Zhao. (2023) Lenvatinib plus immune checkpoint inhibitors or locoregional therapy in unresectable hepatocellular carcinoma: Lessons learned and moving forwards. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:1, pages 188841.
Crossref
Crossref
Ran You, Qingyu Xu, Qi Wang, Qingqiao Zhang, Weizhong Zhou, Chi Cao, Xiangzhong Huang, Honghai Ji, Penghua Lv, Hao Jiang, You Lu, Yong Jin, Yongjun Li, Long Cheng, Weidong Wang, Hao Xu, Xiaoli Zhu & Guowen Yin. (2022) Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study. Frontiers in Oncology 12.
Crossref
Crossref
Yuchen Wan, Zhixue Wang, Ning Yang & Fenye Liu. (2022) Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review. Frontiers in Oncology 12.
Crossref
Crossref
Lei Zhao, Nijia Chang, Lei Shi, Fengyi Li, Fanglin Meng, Xiaohui Xie, Zhe Xu & Fusheng Wang. (2022) Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study. Heliyon 8:6, pages e09538.
Crossref
Crossref
Xinlei Hou, Xueliang Shi & Jie Luo. (2022) Efficacy and safety of camrelizumab (a PD‑1 inhibitor) combined with chemotherapy as a neoadjuvant regimen in patients with locally advanced non‑small cell lung cancer. Oncology Letters 24:1.
Crossref
Crossref
Qi Li, Mengran Cao, Guosheng Yuan, Xiao Cheng, Mengya Zang, Ming Chen, Xiaoyun Hu, Jing Huang, Rong Li, Yabing Guo, Jian Ruan & Jinzhang Chen. (2022) Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study. Frontiers in Oncology 12.
Crossref
Crossref
Qing-Yu Xie, Hai-Yan Liu, Ze-Yi Guo, Yan-Ping Wu, Guo-Lin He, Lei Cai, Ming-Xin Pan & Shun-Jun Fu. (2022) Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy. Frontiers in Molecular Biosciences 8.
Crossref
Crossref